Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 20,000 Shares of Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMAGet Free Report) Director Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $10.77, for a total value of $215,400.00. Following the sale, the director now directly owns 761,283 shares of the company’s stock, valued at $8,199,017.91. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Cyrus Harmon also recently made the following trade(s):

  • On Monday, June 3rd, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.93, for a total value of $54,650.00.
  • On Friday, May 31st, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.41, for a total value of $141,150.00.
  • On Monday, May 6th, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.92, for a total value of $54,600.00.
  • On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total value of $142,650.00.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $10.41 on Wednesday. The stock has a 50-day simple moving average of $10.87 and a 200-day simple moving average of $11.99. Olema Pharmaceuticals, Inc. has a fifty-two week low of $7.78 and a fifty-two week high of $17.79.

Olema Pharmaceuticals (NASDAQ:OLMAGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03). On average, research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OLMA has been the subject of several research reports. The Goldman Sachs Group initiated coverage on Olema Pharmaceuticals in a report on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a report on Tuesday, June 4th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $22.00.

Read Our Latest Report on OLMA

Institutional Trading of Olema Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its stake in Olema Pharmaceuticals by 3.4% during the 1st quarter. California State Teachers Retirement System now owns 34,695 shares of the company’s stock valued at $393,000 after acquiring an additional 1,132 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Olema Pharmaceuticals by 9.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,951 shares of the company’s stock valued at $224,000 after acquiring an additional 1,367 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Olema Pharmaceuticals by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock worth $298,000 after purchasing an additional 1,486 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Olema Pharmaceuticals during the 3rd quarter worth approximately $35,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Olema Pharmaceuticals by 66.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,562 shares of the company’s stock worth $120,000 after buying an additional 4,221 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Olema Pharmaceuticals

(Get Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

Read More

Insider Buying and Selling by Quarter for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.